GLUE Monte Rosa Therapeutics, Inc.
Healthcare$18.81-0.37%ClosedMarket Cap: $1.22B
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
2.36
P/S
28.52
EV/EBITDA
-7.89
DCF Value
$23.34
FCF Yield
-1.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
95.3%
Operating Margin
-345.2%
Net Margin
-302.7%
ROE
-41.0%
ROA
-17.7%
ROIC
-21.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $4.2M | 51.8% | $-50.0M | $-44.5M | $— | — |
| Q4 null | $2.8M | 100.0% | $-49.7M | $-46.1M | $— | — |
| FY null | $123.7M | 93.2% | $-54.2M | $-38.6M | $— | — |
| Q3 null | $12.8M | 100.0% | $-33.0M | $-27.1M | $— | — |
| Q2 null | $23.2M | 100.0% | $-15.6M | $-12.3M | $— | — |
| Q1 null | $84.9M | 100.0% | $44.0M | $46.9M | $— | — |
| Q4 null | $60.6M | 100.0% | $13.0M | $13.4M | $— | — |
| FY null | $75.6M | 89.3% | $-81.1M | $-72.7M | $— | — |
| Q3 null | $9.2M | 100.0% | $-26.5M | $-23.9M | $— | — |
| Q2 null | $4.7M | 56.1% | $-32.6M | $-30.3M | $— | — |
| Q1 null | $1.1M | -78.3% | $-34.9M | $-32.0M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-34.9M | $-33.3M | $-0.58 | — |